Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Ovid Therapeutics Inc. (OVID) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates"
07/31/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
05/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors • Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases • Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs • Development to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizures • Ovid to invest $10 million in preferred equity in Graviton and will fund development programs • Transaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sal..."
04/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting • Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studies • Sustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet patients were documented for up to two years • Sustained reductions were also seen in the frequency of all-seizures from baseline for up to 2 years across both cohorts • A separate post-hoc study of the Phase 2 ELEKTRA study presented at the meeting found a reduction in median seizure frequency across multiple seizure types measured NEW YORK, April 27, 2023 – Ovid Therapeutics Inc. re..."
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/13/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G/A LEVIN JEREMY M reports a 10% stake in OVID THERAPEUTICS INC.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G/A EcoR1 Capital, LLC reports a 8.7% stake in Ovid Therapeutics Inc.
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
05/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/29/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/16/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/15/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2022 10-K Annual Report for the period ended December 31, 2021
03/15/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results • Ovid executing on its strategy to build a leading epilepsy pipeline • OV329 expected to enter the clinic in 2022 • Organization reshaped to reduce personnel by 20% and increase operational efficiency • Targeted business development continues to support the pipeline NEW YORK, March 15, 2022 -- Ovid Therapeutics Inc. , a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. "Ovid is disciplined in our focus to become a leader in epilepsy therapies. We are..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy